OSIVAX
↗Lyon, France
OSIVAX is a clinical-stage biopharmaceutical company leveraging its proprietary oligoDOM® self-assembling nanoparticle platform to develop transformative, first-in-class pan-respiratory virus vaccines. Founded in 2017 as a spin-off from IMAXIO, the company focuses on creating universal vaccines that generate both superior T-cell and sustained B-cell immune responses. The oligoDOM® technology is uniquely designed to target invariant, internal viral antigens, enabling protection against both current and future virus strains or variants. OSIVAX's strategic vision is to develop pan-respiratory vaccines in a single shot that could prevent all strains of influenza and variants of sarbecoviruses, addressing a critical global public health need for universal protection against constantly mutating respiratory pathogens.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$42.2M
Investors:Meiji Seika Pharma Co., Ltd (Series B investor, March 2025), Biomedical Advanced Research and Development Authority (BARDA, $19.5M grant August 2025), Gates Foundation, National Institute of Allergy and Infectious Diseases (NIAID), Issarts Capital, CapHorn Invest, Le territoire en Wallonie, Anaxago
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2b (OVX836)
Modalities:Self-assembling nanoparticles, Protein-based vaccine
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:IMAXIO (spin-off in 2017, but functionally independent; shares patent portfolio)
Subsidiaries:OSIVAX subsidiary in Liège, Belgium
Key Partnerships:KM Biologics - Exclusive license option for Japan market (September 2024), Meiji Seika Pharma - Strategic investor and collaboration partner (March 2025), BARDA/HHS - US government support for vaccine development, Cochin-Pasteur Hospital/APHP - Clinical trial site for OVX033 Phase 1
COMPETITION
Position:Emerging
Competitors:Moderna (mRNA-based approach, formerly in flu vaccine space), Imutex (Flu-v T-cell vaccine in Phase 2), NIAID/Vaccine Research Center (VRC) - mRNA-based candidate in Phase 1, GSK/Sanofi (traditional influenza vaccines), Codagenix, AlloVir, CureVac AG
LEADERSHIP
Key Executives:
Alexandre Le Vert - Co-Founder & CEO
Florence Nicolas - Co-Founder & Chief Development Officer
Fergal Hill - Co-Founder & Chief Scientific Officer (CSO)
Scientific Founders:Alexandre Le Vert, Florence Nicolas, Fergal Hill
Board Members:Dr. Michael Watson (Board Member), Dr. Chris Martin (Board Member), Prof. Jeffrey Almond (Chairman of Scientific Advisory Board)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with OSIVAX. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.